Venous Thromboembolism (VTE) Overview
Learn About Venous Thromboembolism (VTE)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Billings Clinic
Irene Lohkamp is a Geriatrics specialist and a Palliative Medicine provider in Billings, Montana. Dr. Lohkamp and is rated as an Experienced provider by MediFind in the treatment of Venous Thromboembolism (VTE). Her top areas of expertise are Dementia, End-Stage Renal Disease (ESRD), Vitamin D Deficiency, and Cerebellar Degeneration. Dr. Lohkamp is currently accepting new patients.
Scl Health Medical Group - Billings LLC
Jeffrey Johnson is an Internal Medicine provider in Billings, Montana. Dr. Johnson and is rated as an Experienced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, and Maturity Onset Diabetes of the Young. Dr. Johnson is currently accepting new patients.
Scl Health Medical Group - Billings LLC
Edward Malters is an Internal Medicine provider in Billings, Montana. Dr. Malters and is rated as an Experienced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Sitosterolemia, Hypothyroidism, Urinary Tract Infection (UTI), Hip Replacement, and Endoscopy. Dr. Malters is currently accepting new patients.
Summary: This is an observational study in which the data from children with congenital heart disease will be collected and studied. These children will include those who are prescribed rivaroxaban by their doctors after a heart surgery called the Fontan procedure. Congenital heart disease (CHD) is a heart problem that some children are born with. It sometimes requires a surgery called the Fontan procedure...
Summary: The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.